Printer Friendly

TELOR OPHTHALMIC PHARMACEUTICALS BEGINS CLINICAL TRIALS WITH PRODUCT TO PREVENT EYE SURGERY COMPLICATION

 TELOR OPHTHALMIC PHARMACEUTICALS BEGINS CLINICAL TRIALS
 WITH PRODUCT TO PREVENT EYE SURGERY COMPLICATION
 WOBURN, Mass., April 7 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. today announced that the company has begun clinical trials of a drug to prevent acute increases in intraocular pressure that can occur in patients following eye surgery. The product is administered into the eye at the time of surgery by the ophthalmic surgeon and is the company's first to enter clinical trials. The Telor product contains as its active ingredient EY-105, a pharmaceutical specifically designed to increase fluid outflow from the eye.
 "EY-105 represents a unique pharmaceutical approach to preventing increases in intraocular pressure," said Arthur H. Neufeld, Ph.D., chief scientific officer of Telor. "In preclinical trials, our product has demonstrated significant promise in safely and effectively reducing intraocular pressure." Acute increases in intraocular pressure represent a risk in approximately 1.6 million cataract surgeries performed annually in the United States. Transient, post- operative elevations in intraocular pressure can result in damage to the optic nerve and the surgical wound site as well as cause patient discomfort.
 "The start of our clinical program marks a significant milestone for Telor and highlights our strategy of developing a new generation of ophthalmic pharmaceuticals that act by novel mechanisms," commented Stephen J. Riggi, Ph.D., president and chief executive officer of Telor. He added the Telor is also developing a topical product based on EY-105 for long term use in controlling intraocular pressure in patients with glaucoma. The glaucoma product is in preclinical development.
 The initial clinical study is a double-masked, placebo-controlled Phase I/II trial designed to assess the safety and efficacy of EY-105 in patients with glaucoma undergoing cataract surgery, individuals who are at high risk of ocular injury from an increase in intraocular pressure. The study is being conducted by Michael A. Kass, M.D., Professor, Department of Ophthalmology, Wsahington University School of Medicine in St. Louis. The trial is proceeding under an IND (Investigational New Drug Exemption) submitted by the company earlier this year to the U.S. Food and Drug Administration.
 Telor has an exclusive worldwide license from the Massachusetts Eye and Ear Infirmary to patents issued in the United States and Canada and pending in other major world markets covering the use of EY-105 in lowering intraocular pressure. The active ingredient in the Telor product has been used for approximately 25 years as a systemic drug for the treatment of fluid retention resulting from congestive heart failure, cirrhosis of the liver, and kidney disease.
 Telor Ophthalmic Pharmaceuticals, Inc. is developing innovative products for the treatment of age-related eye diseases. The company's initial products in development are for controlling intraocular pressure following surgery and in glaucoma and for other diseases of the eye. Telor began operations in 1989 and has its headquarters in Woburn, Mass.
 -0- 4/7/92
 /CONTACT: Dr. Stephen Riggi of Telor Ophthalmic Pharmaceuticals, Inc., 617-937-0393; or Lynne Brum of Feinstein Partners, 617-577-8110, for Telor/ CO: Telor Ophthalmic Pharmaceuticals ST: Massachusetts IN: MTC SU: PDT


TM -- NE007 -- 5788 04/07/92 11:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1992
Words:512
Previous Article:DURACELL U.S.A. APPOINTS KIERNAN PRESIDENT
Next Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR APRIL 7, 1992


Related Articles
FREDERICK H. GARBER JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC. AS VICE PRESIDENT OF MARKETING
TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS MANUFACTURING TEAM: ADDS DIRECTOR OF TECHNICAL OPERATIONS AND MANAGER OF PRODUCTION
TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS REGULATORY AFFAIRS GROUP; APPOINTS DIRECTOR, REGULATORY AFFAIRS AND COMPLIANCE OFFICER
TELOR OPHTHALMIC PHARMACEUTICALS, INC. SELLS 375,000 SHARES OF COMMON STOCK THROUGH EXERCISE OF OVER-ALLOTMENT
TELOR APPOINTS MICHAEL H. SILVERMAN, M.D., TO EXECUTIVE DIRECTOR, CLINICAL RESEARCH
TELOR OPHTHALMIC PHARMACEUTICALS, INC. INITIATES PHASE II CLINICAL TRIALS TO EVALUATE TEKRON AS A NEW TREATMENT FOR GLAUCOMA
TELOR OPHTHALMIC PHARMACEUTICALS, INC. RECEIVES CLEARANCE IN UK TO BEGIN PHASE III TRIALS FOR DRUG TO PREVENT EYE SURGERY COMPLICATION
TELOR REPORTS SECOND QUARTER AND SIX MONTHS 1993 FINANCIAL RESULTS
TELOR OPHTHALMIC PHARMACEUTICALS TO REVISE TEKRON DEVELOPMENT PROGRAM BASED ON PHASE IIA CLINICAL STUDY
TELOR REPORTS THIRD QUARTER AND NINE MONTHS 1993 FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters